Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.237
Neutral
RSI(14)
46.189
Neutral
STOCH(KDJ)(9,3,3)
19.131
Neutral
ATR(14)
0.343
Low Volatility
CCI(14)
-109.223
Sell
Williams %R
77.876
Sell
TRIX(12,20)
0.087
Sell
StochRSI(14)
73.397
Buy
Shattuck Labs Inc
STTK3.770USD
+0.200+5.60%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
238.08MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Shattuck Labs Inc
Currency: USD Updated: 2026-02-06Key Insights
Shattuck Labs Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.25.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Shattuck Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Shattuck Labs Inc Highlights
StrengthsRisks
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 777.45% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.72M.
Undervalued
The company’s latest PE is -3.81, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 35.95M shares, increasing 10.17% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 216.87K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 6.26.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.250
Target Price
+103.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Shattuck Labs Inc is 7.63, ranking 92 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.00M, representing a year-over-year decrease of 66.63%, while its net profit experienced a year-over-year decrease of 39.69%.
Score
Financials
9.61
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.96
Operational Efficiency
3.10
Growth Potential
10.00
Shareholder Returns
7.50
Shattuck Labs Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Shattuck Labs Inc is 6.80, ranking 220 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.81, which is -86.13% below the recent high of -0.53 and -52.47% above the recent low of -5.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 104/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Shattuck Labs Inc is 7.71, ranking 271 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 6.00 and a low of 2.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.250
Target Price
+103.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Shattuck Labs Inc
STTK
7
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Shattuck Labs Inc is 6.88, ranking 144 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.59 and the support level at 3.23, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.788
Sell
MA10
3.913
Sell
MA20
4.206
Sell
MA50
3.587
Buy
MA100
2.828
Buy
MA200
1.915
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Shattuck Labs Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 56.82%, representing a quarter-over-quarter increase of 9.88%. The largest institutional shareholder is The Vanguard, holding a total of 2.38M shares, representing 3.76% of shares outstanding, with 25.02% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
OrbiMed Advisors, LLC
Adage Capital Management, L.P.
Redmile Group, LLC
Prosight Capital
Hornblower Capital Holdings, LLC
Houghton Capital Holdings, LLC
683 Capital Management LLC
The Clark Estates Inc.
Pinnacle Associates Ltd.
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Shattuck Labs Inc is 2.30, ranking 238 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.58
VaR
+8.27%
240-Day Maximum Drawdown
+61.68%
240-Day Volatility
+125.35%
Return
Best Daily Return
60 days
+20.60%
120 days
+26.73%
5 years
+130.33%
Worst Daily Return
60 days
-7.27%
120 days
-16.36%
5 years
-44.99%
Sharpe Ratio
60 days
+3.74
120 days
+3.37
5 years
+0.14
Risk Assessment
Maximum Drawdown
240 days
+61.68%
3 years
+93.45%
5 years
+98.06%
Return-to-Drawdown Ratio
240 days
+1.93
3 years
+0.09
5 years
-0.18
Skewness
240 days
+2.63
3 years
+5.42
5 years
+5.29
Volatility
Realised Volatility
240 days
+125.35%
5 years
+121.34%
Standardised True Range
240 days
+4.67%
5 years
+12.69%
Downside Risk-Adjusted Return
120 days
+705.36%
240 days
+705.36%
Maximum Daily Upside Volatility
60 days
+67.75%
Maximum Daily Downside Volatility
60 days
+51.88%
Liquidity
Average Turnover Rate
60 days
+4.21%
120 days
+2.30%
5 years
--
Turnover Deviation
20 days
+625.76%
60 days
+177.85%
120 days
+51.55%
Peer Comparison
Biotechnology & Medical Research
Shattuck Labs Inc
STTK
6.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
